125 related articles for article (PubMed ID: 22901566)
1. Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis.
Zambon CF; Prayer-Galetti T; Basso D; Padoan A; Rossi E; Secco S; Pelloso M; Fogar P; Navaglia F; Moz S; Zattoni F; Plebani M
J Urol; 2012 Oct; 188(4):1124-30. PubMed ID: 22901566
[TBL] [Abstract][Full Text] [Related]
2. Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men.
Nobata S; Hishida A; Naito M; Asai Y; Mori A; Kuwabara M; Katase S; Okada R; Morita E; Kawai S; Hamajima N; Wakai K
Urol Int; 2012; 89(1):39-44. PubMed ID: 22433834
[TBL] [Abstract][Full Text] [Related]
3. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
[TBL] [Abstract][Full Text] [Related]
4. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
[TBL] [Abstract][Full Text] [Related]
5. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels.
Parikh H; Wang Z; Pettigrew KA; Jia J; Daugherty S; Yeager M; Jacobs KB; Hutchinson A; Burdett L; Cullen M; Qi L; Boland J; Collins I; Albert TJ; Vatten LJ; Hveem K; Njølstad I; Cancel-Tassin G; Cussenot O; Valeri A; Virtamo J; Thun MJ; Feigelson HS; Diver WR; Chatterjee N; Thomas G; Albanes D; Chanock SJ; Hunter DJ; Hoover R; Hayes RB; Berndt SI; Sampson J; Amundadottir L
Hum Genet; 2011 Jun; 129(6):675-85. PubMed ID: 21318478
[TBL] [Abstract][Full Text] [Related]
6. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer.
Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M
J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705
[TBL] [Abstract][Full Text] [Related]
7. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.
Penney KL; Schumacher FR; Kraft P; Mucci LA; Sesso HD; Ma J; Niu Y; Cheong JK; Hunter DJ; Stampfer MJ; Hsu SI
Carcinogenesis; 2011 Jun; 32(6):853-9. PubMed ID: 21421545
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
[TBL] [Abstract][Full Text] [Related]
9. Frequency of KLK3 gene deletions in the general population.
Rodriguez S; Al-Ghamdi OA; Guthrie PA; Shihab HA; McArdle W; Gaunt T; Alharbi KK; Day IN
Ann Clin Biochem; 2017 Jul; 54(4):472-480. PubMed ID: 27555663
[TBL] [Abstract][Full Text] [Related]
10. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
Choi SY; Kim HJ; Cheong HS; Myung SC
Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
[TBL] [Abstract][Full Text] [Related]
11. Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.
Beikzadeh B; Angaji SA; Abolhasani M
BMC Med Genet; 2020 Apr; 21(1):81. PubMed ID: 32295536
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
13. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
[TBL] [Abstract][Full Text] [Related]
14. Genetic correction of PSA values using sequence variants associated with PSA levels.
Gudmundsson J; Besenbacher S; Sulem P; Gudbjartsson DF; Olafsson I; Arinbjarnarson S; Agnarsson BA; Benediktsdottir KR; Isaksson HJ; Kostic JP; Gudjonsson SA; Stacey SN; Gylfason A; Sigurdsson A; Holm H; Bjornsdottir US; Eyjolfsson GI; Navarrete S; Fuertes F; Garcia-Prats MD; Polo E; Checherita IA; Jinga M; Badea P; Aben KK; Schalken JA; van Oort IM; Sweep FC; Helfand BT; Davis M; Donovan JL; Hamdy FC; Kristjansson K; Gulcher JR; Masson G; Kong A; Catalona WJ; Mayordomo JI; Geirsson G; Einarsson GV; Barkardottir RB; Jonsson E; Jinga V; Mates D; Kiemeney LA; Neal DE; Thorsteinsdottir U; Rafnar T; Stefansson K
Sci Transl Med; 2010 Dec; 2(62):62ra92. PubMed ID: 21160077
[TBL] [Abstract][Full Text] [Related]
15. Association of gene polymorphisms of KLK3 and prostate cancer: A meta-analysis.
Li H; Fei X; Shen Y; Wu Z
Adv Clin Exp Med; 2020 Aug; 29(8):1001-1009. PubMed ID: 32869960
[TBL] [Abstract][Full Text] [Related]
16. Kallikrein 3 and vitamin D receptor polymorphisms: potentials environmental risk factors for prostate cancer.
Hu J; Qiu Z; Zhang L; Cui F
Diagn Pathol; 2014 Apr; 9():84. PubMed ID: 24755043
[TBL] [Abstract][Full Text] [Related]
17. Association between three genetic variants in kallikrein 3 and prostate cancer risk.
Ding WH; Ren KW; Yue C; Zou JG; Zuo L; Zhang LF; Bai Y; Okada A; Yasui T; Mi YY
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30413614
[TBL] [Abstract][Full Text] [Related]
18. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
19. Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
Chen R; Huang Y; Cai X; Xie L; He D; Zhou L; Xu C; Gao X; Ren S; Wang F; Ma L; Wei Q; Yin C; Tian Y; Sun Z; Fu Q; Ding Q; Zheng J; Ye Z; Ye D; Xu D; Hou J; Xu K; Yuan J; Gao X; Liu C; Pan T; Sun Y;
PLoS One; 2015; 10(6):e0130308. PubMed ID: 26091007
[TBL] [Abstract][Full Text] [Related]
20. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
